Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer

Journal of Translational Medicine

Xiangdong Wang⁴  Francesco Marincola³  William Wang¹  Ding Zhang²  Zhihui Min⁴  Jiebai Zhou² 

[1]Department of Biomedical Sciences, UCL, London, UK

[2]Department of Pulmonary Medicine, Shanghai, China

[3]Sidra Medical and Research Centre, Doha, Qatar

[4]Fudan University Center for Clinical Bioinformatics, Shanghai, China

关键词: Microenvironment;    Lymphocytes;    Lung cancer;    Regulatory B cells;    Regulatory T cells;   

Others  :  1147215
DOI  :  10.1186/s12967-014-0304-0

 received in 2014-09-08, accepted in 2014-10-21,  发布年份 2014

【 摘 要 】

Background

Regulatory T cells (Tregs) and B cells (Bregs) play an important role in the development of lung cancer. The present study aimed to investigate the phenotype of circulating Tregs and Bregs in patients with lung cancer and explore potential mechanism by which lung cancer cells act on the development of both.

Methods

Patients with lung cancer (n?=?268) and healthy donors (n?=?65) were enrolled in the study. Frequencies of Tregs and Bregs were measured by flow cytometry with antibodies against CD4, CD25, CD127, CD45RA, CD19, CD24, CD27 and IL-10 before and after co-cultures. qRT-PCR was performed to evaluate the mRNA levels of RANTES, MIP-1?, TGF-?, IFN-? and IL-4.

Results

We found a lower frequency of Tregs and a higher frequency of Bregs in patients with lung cancer compared to healthy donors. Co-culture of lung cancer cells with peripheral blood mononuclear cells could polarize the lymphocyte phenotype in the similar pattern. Lipopolysaccharide (LPS)-stimulated lung cancer cells significantly modulated regulatory cell number and function in an in vitro model.

Conclusion

We provide initial evidence that frequencies of peripheral Tregs decreased or Bregs increased in patients with lung cancer, which may be modulated directly by lung cancer cells. It seems cancer cells per se plays a crucial role in the development of tumor immunity.

【 授权许可】

   
2014 Zhou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2003, 63:11-30.
• [2][http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/] webcite World Health Organization: The global burden of disease: 2004 update. In []
• [3]Johansson M, Denardo DG, Coussens LM: Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154.
• [4]Riddell SR: Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med 2004, 200:1533-1537.
• [5]Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
• [6]Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275-293.
• [7]Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
• [8]Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T: CD4?+?CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005, 14:1269-1273.
• [9]Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN: Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001, 31:1122-1131.
• [10]Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
• [11]Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K: Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010, 5:585-590.
• [12]Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V: FOXP3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 2011, 6:432-438.
• [13]Lundy SK: Killer B lymphocytes: the evidence and the potential. Inflamm Res 2009, 58:345-357.
• [14]Vitale G, Mion F, Pucillo C: Regulatory B cells: evidence, developmental origin and population diversity. Mol Immunol 2010, 48:1-8.
• [15]Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M: Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010, 184:4801-4809.
• [16]DiLillo DJ, Matsushita T, Tedder TF: B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010, 1183:38-57.
• [17]Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A: Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res 2011, 71:3505-3515.
• [18]Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
• [19]Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, McElrath MJ: Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007, 322:57-69.
• [20]Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE, Gibot S: The relationship between CD4?+?CD25?+?CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care 2010, 14:R19. BioMed Central Full Text
• [21]Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541.
• [22]Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF: A regulatory B-cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
• [23]Woo EY, Yeh H, Chu CS, Schleinger K, Carroll RG, Riley JL, Kaiser LR, June CH: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002, 168:4272-4276.
• [24]Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Ge Y, Johnson DE, Ju S, Shu Y: CD13?+?CD4?+?CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle 2009, 8:2578-2585.
• [25]Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 2006, 438:820-827.
• [26]Sallusto F, Geginat J, Lanzavecchia A: Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
• [27]Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S, Nanan R, Fazekas de Saint Groth B: Persistence of naïve CD45RA?+?regulatory T cells in adult life. Blood 2006, 107:2830-2838.
• [28]Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG: RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002, 8:3803-3812.
• [29]Konishi T, Okabe H, Katoh H, Fujiyama Y, Mori A: Macrophage inflammatory protein-1 alpha expression in non-neoplastic and neoplastic lung tissue. Vichows Arch 1996, 428:107-111.
• [30]Wang XD, Peer D, Petersen B: Molecular and Cellular Therapies: New challenges and opportunities. Mol Cell Therap 2013, 1:1. BioMed Central Full Text
• [31]Wu XD, Chen LN, Wang XD: Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases. Clin Transl Med 2014, 3:16. BioMed Central Full Text
• [32]Zhu Z, Wang DC, Popescu LM, Wang XD: Single-cell transcriptome in the identification of disease biomarkers: opportunities and challenges. J Transl Med 2014, 12:212. BioMed Central Full Text
• [33]Wang XD: Role of clinical bioinformatics in the development of network-based Biomarkers. J Clin Bioinforma 2011, 1:28. BioMed Central Full Text
• [34]Wu DJ, Zhu BJ, Wang XD: Metabonomics-based omics study and atherosclerosis. J Clin Bioinforma 2011, 1:30. BioMed Central Full Text
• [35]Wang XD, Liotta L: Clinical bioinformatics: a new emerging science. J Clin Bioinforma 2011, 1:1. BioMed Central Full Text
• [36]Taylor MA, Schiemann WP: Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Therap 2014, 2:30. BioMed Central Full Text
• [37]Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, Blandino G: MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Therap 2014, 2:16. BioMed Central Full Text
• [38]Frantzi M, Bhat A, Latosinska A: Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med 2014, 3:7. BioMed Central Full Text